Please assess the completion status of the following clinical trial:

Trial Title: First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed colorectal adenocarcinoma;~* Availability of formalin-fixed paraffin embedded tumor block from primary and/or metastasis;~* BRAF V600E mutant status of primary colorectal cancer and/or related metastasis;~* Unresectable and measurable metastatic disease according to RECIST criteria;~* Male or female, aged \> 18 years and \< 75 years;~* ECOG PS \< 2 if aged \< 71 years;~* ECOG PS = 0 if aged 71-75 years;~* Life expectancy of more than 3 months;~* Adequate haematological function: ANC ≥ 1.5 x 10\^9/L; platelets ≥ 100 x 10\^9/L, Hb ≥ 9 g/dL;~* Adequate liver function: serum bilirubin ≤ 1.5 x ULN; alkaline phosphatase and transaminases ≤ 2.5 x ULN (in case of liver metastases ≤ 5 x ULN);~* Serum creatinine ≤ 1.5 x ULN;~* Previous adjuvant chemotherapy is allowed if more than 12 months have elapsed between the end of adjuvant therapy and first relapse;~* At least 6 weeks from prior extended radiotherapy and 4 weeks from surgery;~* Written informed consent to experimental treatment and molecular analyses.~Exclusion Criteria:~* Presence or history of CNS metastasis;~* Serious, non-healing wound, ulcer, or bone fracture;~* Evidence of bleeding diathesis or coagulopathy;~* Uncontrolled hypertension;~* Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (CVA) (≤6 months before treatment start), myocardial infarction (≤ 6 months before treatment start), unstable angina, NYHA ≥ grade 2 chronic heart failure (CHF), uncontrolled arrhythmia;~* Current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes;~* Chronic, daily treatment with high-dose aspirin (\>325 mg/day);~* Symptomatic peripheral neuropathy ≥ 2 grade NCIC-CTG criteria;~* Active uncontrolled infections;~* Treatment with any investigational drug within 30 days prior to enrolment;~* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of curatively treated basal and squamous cell carcinoma of the skin or in situ cancer of the cervix;~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start;~* Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome;~* Fertile women (\< 2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BRAF mutant mCRC (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).